HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.